Table 3 Retrospective validation of digital twin predicted responses

From: MRI-based digital twins to improve treatment response of breast cancer by optimizing neoadjuvant chemotherapy regimens

Trial

Tested regimens

Digital twin predicted pCR rate

Trial observation

INT C9741

conventional regimen: 4 cycles of A (60 mg/m2) + C (600 mg/m2) every 3 weeks → 4 cycles of T (175 mg/m2) every 3 weeks

49.52%

Dose-dense regimen led to significant better outcome

dose-dense regimen: 4 cycles of A (60 mg/m2) + C (600 mg/m2) every 2 weeks → 4 cycles of T (175 mg/m2) every 2 weeks

73.33%a

ECOG 1199 + 

Tri-weekly Taxol: 4 cycles of A (60 mg/m2) + C (600 mg/m2) every 3 weeks → 4 cycles of T (175 mg/m2) every 3 weeks

49.52%

Weekly and bi-weekly Taxol provided similar outcomes that were superior tri-weekly Taxol

weekly Taxol: 4 cycles of A (60 mg/m2) + C (600 mg/m2) every 3 weeks → 12 cycles of T (80 mg/m2) weekly

55.24%

Bi-weekly Taxol: 4 cycles of A (60 mg/m2) + C (600 mg/m2) every 3 weeks → 4 cycles of T (175 mg/m2) every 2 weeks

60.00%

SWOG S0221

Arm 1: 6 cycles of A (60 mg/m2) + C (600 mg/m2) every 2 weeks → 6 cycles of T (175 mg/m2) every 2 weeks

79.05%

All regimens provided similar outcomes in breast cancer subtypes, while a non-significant benefit was observed for bi-weekly regimen (Arm 1) in TNBC.

Arm 2: 15 cycles of A (24 mg/m2) + C (60 mg/m2) weekly → 6 cycles of T (175 mg/m2) every 2 weeks

72.38%

Arm 3: 6 cycles of A (60 mg/m2) + C (600 mg/m2) every 2 weeks → 12 cycles of T (80 mg/m2) weekly

73.33%

Arm 4: 15 cycles of A (24 mg/m2) + C (60 mg/m2) weekly → 12 cycles of T (80 mg/m2) weekly

69.52%

  1. aIndicates the pCR rate from dose-dense regimen is significantly higher than that from the conventional regimen.
Back to article page